Docoh
Loading...

MRKR Marker Therapeutics

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, the company believes that its product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

Company profile

Ticker
MRKR
Exchange
CEO
Peter Hoang
Employees
Incorporated
Location
Fiscal year end
Former names
EDUVERSE COM, GENEMAX CORP, TAPIMMUNE INC, TAPIMMUNE INC.
SEC CIK
Subsidiaries
Marker Cell Therapy, Inc. • GeneMax Pharmaceuticals, Inc. • GeneMax Pharmaceuticals Canada, Inc. ...
IRS number
880277072

MRKR stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 Aug 21
21 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 57.22M 57.22M 57.22M 57.22M 57.22M 57.22M
Cash burn (monthly) 2.43M (positive/no burn) 3.64M 2.96M 2.28M 2.2M
Cash used (since last report) 9.05M n/a 13.55M 11.04M 8.5M 8.19M
Cash remaining 48.17M n/a 43.67M 46.18M 48.72M 49.04M
Runway (months of cash) 19.8 n/a 12.0 15.6 21.4 22.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Jun 21 Wilson John Robert Common Stock Grant Acquire A No No 0 12,658 0 7,812,008
8 Jun 21 Norman David Eansor Common Stock Grant Acquire A No No 0 12,658 0 36,940
8 Jun 21 Steve Elms Common Stock Grant Acquire A No No 0 12,658 0 29,680
8 Jun 21 David Laskow-Pooley Common Stock Grant Acquire A No No 0 12,658 0 55,223
8 Jun 21 Frederick Gerald Wasserman Common Stock Grant Acquire A No No 0 12,658 0 65,223

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

54.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 75 74 +1.4%
Opened positions 17 22 -22.7%
Closed positions 16 7 +128.6%
Increased positions 17 21 -19.0%
Reduced positions 25 17 +47.1%
13F shares
Current Prev Q Change
Total value 103.96M 96.15M +8.1%
Total shares 45.59M 43.81M +4.0%
Total puts 142.7K 395.6K -63.9%
Total calls 359.7K 245.8K +46.3%
Total put/call ratio 0.4 1.6 -75.4%
Largest owners
Shares Value Change
New Enterprise Associates 16 14.46M $26.9M 0.0%
NEA Management 10.71M $29.89M 0.0%
Eastern Capital 3.97M $0 0.0%
Aisling Capital Management 3.14M $8.77M 0.0%
Vanguard 2.69M $7.51M +5.6%
Millennium Management 1.36M $3.81M +515.8%
Two Sigma Advisers 1.35M $3.78M +842.7%
Two Sigma Investments 1M $2.79M +816.1%
Victory Capital Management 923.68K $2.58M -6.4%
D. E. Shaw & Co. 631.19K $1.76M +2203.7%
Largest transactions
Shares Bought/sold Change
BLK Blackrock 258.55K -1.82M -87.5%
Two Sigma Advisers 1.35M +1.21M +842.7%
Kennedy Capital Management 601.34K -1.21M -66.8%
Millennium Management 1.36M +1.14M +515.8%
Two Sigma Investments 1M +891.13K +816.1%
D. E. Shaw & Co. 631.19K +603.79K +2203.7%
ACT Capital Management, LLLP 420K +420K NEW
Renaissance Technologies 399.9K +399.9K NEW
STT State Street 192.75K -383.47K -66.5%
Marshall Wace 327.83K +327.83K NEW

Financial report summary

?
Risks
  • We are a development stage company with a history of operating losses, and we expect losses to continue for the indefinite future. These factors raise substantial doubt regarding our ability to continue as a going concern.
  • Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community.
  • If we are unable to protect our proprietary rights, we may not be able to compete effectively or operate profitably.
  • The use of our technologies could potentially conflict with the rights of others.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • If we fail to comply with any obligations under our existing license agreements or any future license agreements, or disputes arise with respect to those agreements, it could have a negative impact on our business and our intellectual property rights.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • Certain of our technologies are in-licensed from third parties, and the protection of those technologies is not entirely within our control.
  • We rely upon patents and licensed technologies to protect our technology. We may be unable to protect our intellectual property rights, and we may be liable for infringing the intellectual property rights of others.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
  • If we are unable to obtain licenses needed for the development of our product candidates, or if we breach any of the agreements under which we license rights to patents or other intellectual property from third parties, we could lose license rights that are important to our business.
  • We are subject to extensive regulation, which can be costly, time consuming and can subject us to unanticipated delays. Even if we receive regulatory approval of our product candidates, we will be subject to ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  • Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.
  • Recently enacted and future legislation in the United States and other countries may affect the prices we may obtain for our product candidates and increase the difficulty and cost to commercialize our product candidates.
  • The price of our stock may be volatile.
  • Sales of additional equity securities may adversely affect the market price of our common stock and your rights may be reduced. Our stockholders may experience dilution in the future and it may adversely affect the market price of our securities.
  • The accounting treatment for certain of our warrants is complex and subject to judgments concerning the valuation of embedded derivative rights within the applicable securities. Fluctuations in the valuation of these rights could cause us to take charges to our statement of operations and make our financial results unpredictable.
Management Discussion
  • In this discussion of our results of operations and financial condition, amounts in financial tables, other than per-share amounts, have been rounded to the nearest thousand.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: attorney, awaiting, hearing
Removed: approximate, comprised, defend, equivalent, flat, maximum, professional, vigorously